1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Boehringer Ingelheim’s Pagnotta Talks Adalimumab And Interchangeability

As Cyltezo Rival To Humira Hits US, Firm Says It Is ‘Uniquely Positioned’ In Biosimilars Market

 
• By Dave Wallace

As Boehringer Ingelheim launches the first – and so far, only – interchangeable US adalimumab biosimilar, the firm’s biosimilar commercial brand lead Stephen Pagnotta talks to Generics Bulletin about how the interchangeability designation puts the firm in a unique position when it comes to competing with Humira.

Stephen Pagnotta
Stephen Pagnotta is biosimilar commercial brand lead at Boehringer Ingelheim • Source: Boehringer Ingelheim

In an unprecedently competitive biosimilar market, only one of the several newly-launched US rivals to Humira (adalimumab) boasts a US Food and Drug Administration designation of interchangeability: Boehringer Ingelheim’s Cyltezo (adalimumab-adbm) version. (Also see "First Interchangeable Humira Biosimilar Approved In US" - Generics Bulletin, 18 October, 2021.)

An interchangeability designation allows a pharmacist to substitute a biosimilar for its reference biologic without consulting the original prescriber, subject to US state law

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

 
• By Urtė Fultinavičiūtė

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”